Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Share-based Compensation: 2022-2025

Historic Share-based Compensation for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to $9.3 million.

  • Phathom Pharmaceuticals' Share-based Compensation rose 64.99% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.8 million, marking a year-over-year decrease of 28.96%. This contributed to the annual value of $24.0 million for FY2024, which is 46.59% down from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Share-based Compensation stood at $9.3 million for Q3 2025, which was up 12.39% from $8.3 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Share-based Compensation high stood at $24.6 million for Q4 2023, and its period low was $5.5 million during Q1 2025.
  • In the last 3 years, Phathom Pharmaceuticals' Share-based Compensation had a median value of $6.7 million in 2024 and averaged $8.4 million.
  • As far as peak fluctuations go, Phathom Pharmaceuticals' Share-based Compensation skyrocketed by 269.30% in 2023, and later tumbled by 72.80% in 2024.
  • Phathom Pharmaceuticals' Share-based Compensation (Quarterly) stood at $6.7 million in 2022, then soared by 269.30% to $24.6 million in 2023, then tumbled by 72.80% to $6.7 million in 2024, then spiked by 64.99% to $9.3 million in 2025.
  • Its last three reported values are $9.3 million in Q3 2025, $8.3 million for Q2 2025, and $5.5 million during Q1 2025.